Sofie Gijsel - Galapagos Head Relations
| GLPGF Stock | USD 26.26 1.60 6.49% |
Insider
Sofie Gijsel is Head Relations of Galapagos NV
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Irena Konstantinova | Inventiva Sa | N/A | |
| Dr DACVP | Biohaven Pharmaceutical Holding | 62 | |
| Lina Gugucheva | NewAmsterdam Pharma | 37 | |
| Michael Gerometta | Opthea | 59 | |
| FACC Facc | NewAmsterdam Pharma | 65 | |
| Thomas Lynch | Biohaven Pharmaceutical Holding | N/A | |
| Louise Kooij | NewAmsterdam Pharma | 48 | |
| Astrid MD | Hillevax | 54 | |
| Joseph Ciavarella | Portage Biotech | N/A | |
| MD MBA | Portage Biotech | 56 | |
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
| Pascal Caisey | Genfit | 55 | |
| Pharis Mohideen | DBV Technologies | 59 | |
| Frederic Cren | Inventiva Sa | 58 | |
| Michael Morin | Immunome | 69 | |
| Thomas Baetz | Genfit | 49 | |
| Daniel Tass | DBV Technologies | 64 | |
| Purnanand Sarma | Immunome | 59 | |
| Ian Leitch | Opthea | 61 | |
| Kishen Mehta | Biohaven Pharmaceutical Holding | 35 | |
| Michael Cooreman | Inventiva Sa | 66 | |
Management Performance
| Return On Equity | 0.0021 | |||
| Return On Asset | -0.0119 |
Galapagos NV Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
| Andre Hoekema, Sr. VP of Corporate Devel. | ||
| John Montana, Managing Argenta | ||
| Michele MBA, Chief Board | ||
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
| Marieke Vermeersch, Head Communication | ||
| Chantal Tasset, Head Devel | ||
| Sofie Gijsel, Head Relations | ||
| MBA MBA, COO Pres |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0021 | |||
| Return On Asset | -0.0119 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | (2.11 B) | |||
| Shares Outstanding | 65.84 M | |||
| Shares Owned By Insiders | 26.24 % | |||
| Shares Owned By Institutions | 32.13 % | |||
| Price To Earning | 454.11 X | |||
| Price To Book | 0.92 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Galapagos Pink Sheet
Galapagos financial ratios help investors to determine whether Galapagos Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Galapagos with respect to the benefits of owning Galapagos security.